Cisapride

Bedford, Timothy A.; Rowbotham, David J.

doi:10.2165/00002018-199615030-00002

Cited by 74 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The broad spectrum of activity of itraconazole may be a contributing factor, given that Candida infections of the nail and surrounding tissue seem to be particularly prevalent in diabetic patients [8]. However, itraconazole is capable of inhibiting the metabolism of drugs metabolized by the microsomal enzyme cytochrome P450 (CYP) 3A4, such as cisapride, terfenadine, cyclosporine, lovastatin, midazolam and triazolam [9, 10, 11, 12, 13, 14]. …”

Section: Introductionmentioning

confidence: 99%

Safety of Itraconazole in Diabetic Patients

et al. 1999

View full text Add to dashboard Cite

Background: Onychomycosis and dermatomycoses can result in serious complications in patients with underlying chronic diseases such as diabetes. To avoid these complications, these dermatological disorders need to be treated efficiently, for example with the triazole antifungal itraconazole. Itraconazole can inhibit the metabolism of drugs by CYP 3A4 and therefore might affect the efficacy of antidiabetic agents. Objective: To investigate this, we assessed the safety of itraconazole in diabetic patients with onychomycosis or dermatomycoses. Methods: We reviewed pharmacokinetic and safety data from clinical trials and postmarketing surveillance over the past 10 years. Results: Postmarketing surveillance (a review of all adverse-event reports in patients receiving itraconazole concomitantly with insulin or an oral antidiabetic agent) revealed 15 reports suggestive of hyperglycemia and 9 reports suggestive of hypoglycemia; in most patients, no change in antidiabetic effect was reported. From clinical trials including a total of 189 diabetic patients treated with itraconazole for various infections (mainly systemic infections and vaginal candidiasis), only one itraconazole-related adverse event was recorded; this was a case of aggravated diabetes in a renal transplant recipient who was also receiving cyclosporine. Adverse effects due to drug-drug interactions are not expected in diabetic patients receiving oral antidiabetic agents that are not metabolized through the CYP 3A4 system (e.g. tolbutamide, gliclazide, glibenclamide, glipizide and metformin). Conclusion: Itraconazole can be used safely and efficiently for the treatment of dermatological disorders in diabetic patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety of Itraconazole in Diabetic Patients

et al. 1999

View full text Add to dashboard Cite

show abstract

“…A population PK model for midazolam in children was developed based on concentration-time data, to establish a pediatric covariate function for midazolam clearance. Next, we selected a range of drugs that are CYP3A substrates that are commonly prescribed in children, covering compounds prescribed for varying indications in different therapeutic areas, with oral or intravenous administration, and with different drug properties, i.e., alprazolam (14), atorvastatin (15), cisapride (16), domperidone (17), quinidine (18), sildenafil (19), simvastatin (20), solifenacin (21), sufentanil (22), sirolimus (23), tacrolimus (24), tamsulosin (25), and vincristine (26). Based on the drug properties of these CYP3A substrates, we used the framework of Calvier et al (7) to define which age the covariate function for midazolam can be used for accurate scaling of pediatric clearance of the CYP3A substrates from adult clearance values.…”

Section: Methodsmentioning

confidence: 99%

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children

Brussee

Krekels

Calvier

et al. 2019

AAPS J

View full text Add to dashboard Cite

Recently a framework was presented to assess whether pediatric covariate models for clearance can be extrapolated between drugs sharing elimination pathways, based on extraction ratio, protein binding, and other drug properties. Here we evaluate when a pediatric covariate function for midazolam clearance can be used to scale clearance of other CYP3A substrates. A population PK model including a covariate function for clearance was developed for midazolam in children aged 1–17 years. Commonly used CYP3A substrates were selected and using the framework, it was assessed whether the midazolam covariate function accurately scales their clearance. For eight substrates, reported pediatric clearance values were compared numerically and graphically with clearance values scaled using the midazolam covariate function. For sildenafil, clearance values obtained with population PK modeling based on pediatric concentration-time data were compared with those scaled with the midazolam covariate function. According to the framework, a midazolam covariate function will lead to systemically accurate clearance scaling (absolute prediction error (PE) < 30%) for CYP3A substrates binding to albumin with an extraction ratio between 0.35 and 0.65 when binding < 10% in adults, between 0.05 and 0.55 when binding > 90%, and with an extraction ratio ranging between these values when binding between 10 and 90%. Scaled clearance values for eight commonly used CYP3A substrates were reasonably accurate (PE < 50%). Scaling of sildenafil clearance was accurate (PE < 30%). We defined for which CYP3A substrates a pediatric covariate function for midazolam clearance can accurately scale plasma clearance in children. This scaling approach may be useful for CYP3A substrates with scarce or no available pediatric PK information. Electronic supplementary material The online version of this article (10.1208/s12248-019-0351-9) contains supplementary material, which is available to authorized users.

show abstract

Prophylactic fluconazole promotes reepithelialization in full-face carbon dioxide laser skin resurfacing

Conn¹,

Nanda²

2000

Lasers Surg. Med.

View full text Add to dashboard Cite

Cisapride

Cited by 74 publications

References 19 publications

Safety of Itraconazole in Diabetic Patients

Safety of Itraconazole in Diabetic Patients

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children

Prophylactic fluconazole promotes reepithelialization in full-face carbon dioxide laser skin resurfacing

Contact Info

Product

Resources

About